Literature DB >> 30111968

Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

C A Kim1, S Ahmed1, S Ahmed1, B Brunet2, H Chalchal2, R Deobald2, C Doll3, M P Dupre1, V Gordon1, R M Lee-Ying3, H Lim4, D Liu4, J M Loree4, J P McGhie4, K Mulder3, J Park1, B Yip1, R P Wong1, A Zaidi2.   

Abstract

The 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference (wcgccc) was held in Winnipeg, Manitoba, 29-30 September 2017. The wcgccc is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of colorectal cancer.

Entities:  

Keywords:  Colorectal cancer; adjuvant chemotherapy; immunotherapy; molecular tests; radioembolization; sidedness; surgery

Mesh：

Year:  2018        PMID： 30111968      PMCID： PMC6092050          DOI： 10.3747/co.25.4109

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  73 in total

1.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Authors:  Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Briant Fruth; Jeffrey A Meyerhardt; Deborah Schrag; Claire Greene; Bert H O'Neil; James Norman Atkins; Scott Berry; Blase N Polite; Eileen M O'Reilly; Richard M Goldberg; Howard S Hochster; Richard L Schilsky; Monica M Bertagnolli; Anthony B El-Khoueiry; Peter Watson; Al B Benson; Daniel L Mulkerin; Robert J Mayer; Charles Blanke
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

2.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

3.  Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).

Authors:  Frank A Sinicrope; Michelle R Mahoney; Harry H Yoon; Thomas C Smyrk; Stephen N Thibodeau; Richard M Goldberg; Garth D Nelson; Daniel J Sargent; Steven R Alberts
Journal:  Clin Cancer Res       Date:  2015-07-17       Impact factor: 12.531

Review 4.  RAS and BRAF in metastatic colorectal cancer management.

Authors:  Jun Gong; May Cho; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2016-10

5.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Authors:  Julian Walter Holch; Ingrid Ricard; Sebastian Stintzing; Dominik Paul Modest; Volker Heinemann
Journal:  Eur J Cancer       Date:  2016-11-29       Impact factor: 9.162

6.  BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

Authors:  Matthew F Kalady; Kathryn L Dejulius; Julian A Sanchez; Awad Jarrar; Xiuli Liu; Elena Manilich; Marek Skacel; James M Church
Journal:  Dis Colon Rectum       Date:  2012-02       Impact factor: 4.585

7.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

8.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.

Authors:  Fausto Petrelli; Giovanni Sgroi; Enrico Sarti; Sandro Barni
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

9.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Authors:  Sabine Tejpar; Sebastian Stintzing; Fortunato Ciardiello; Josep Tabernero; Eric Van Cutsem; Frank Beier; Regina Esser; Heinz-Josef Lenz; Volker Heinemann
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

10.  Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.

Authors:  Lizhen Zhu; Caixia Dong; Ying Cao; Xuefeng Fang; Chenhan Zhong; Dan Li; Ying Yuan
Journal:  PLoS One       Date:  2016-05-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.